跳至主要内容

Hit Identification in Drug Discovery

 Medicilon’s Chemistry department has more than 100 chemists, who are experienced in the cooperation with major domestic and international pharmaceutical and biotech companies. Our services cover a variety of research interests in novel drug research, including target validation, hits evaluation, lead optimization, candidate nomination, preclinical development and IND filing.


Medicilon has completed dozens of drug research projects for clients and successfully identified several drug candidates for clinical trials. Our team provides the following services:

  • Target Assessment – Drug Targets
  • HITs Identification
  • Lead Optimization
  • Clinical Candidate Nomination
  • Computer Aided Drug Design
  • SAR Study

Hit discovery technologies range from traditional high-throughput screening to affinity selection of large libraries, fragment-based techniques and computer-aided de novo design, many of which have been extensively reviewed. Development of quality leads using hit confirmation and hit-to-lead approaches present their own challenges, depending on the hit discovery method used to identify the initial hits.

Hit Identification Using Virtual Screening

For hit identification, some information about either the target protein or an active compound is necessary. In the case of a known structure of the protein, a virtual screening of compound libraries leads to virtual hits which will be synthesised and tested afterwards or tested immediately.

If the structure of the natural substrate is known, a ligand based approach will be accomplished. The computer searches for similar compounds and the resulting hits are checked for drug like properties.

Current screening methods in drug discovery include either phenotypic cellular assays with functional read‐outs, or biochemical assays requiring the generation of target‐expressing stable cell lines, and purification of target to screen against a compound library. Secondary and profiling assays are then used to determine compound cell permeability and cytotoxicity. This process can be extremely difficult for some targets such as those forming protein–protein interactions or membrane receptors.

Hit Identification Assay Features

– Protein target can be membrane bound, difficult to produce for standard biochemical assays, and difficult to purify;
– Hit and lead compounds and focused libraries can be screened against protein target within physiological environment;
– Compound cell permeability, specificity and cytotoxicity are assessed in one process;

– Process can be upscaled to screen hundreds of compounds in a few hours.

Hit Identification Assay Applications

  • Primary and secondary medium to high throughput screening in drug discovery
  • Target identification or validation for hit phenotypic screening

 

Contact Us 

Email : marketing@medicilon.com
Tel : +86 021 58591500

Tips : Above is part of hit identification in drug discovery and drug target identification methods. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati